

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1–9. (Canceled)

10. (New) A method for determining a good or poor prognosis for a patient suffering from neuroblastoma, the method comprising:

a. extracting biological material from a biological sample taken from the patient;

b. contacting the biological material with reagents specific for a combination of target genes comprising the nucleic acid sequences set forth in SEQ ID NOs: 2, 3, 7, 8, 10, 22, 25, 29, and 34, respectively;

c. determining expression levels of the target genes; and

d. analyzing the expression levels of the target genes to determine whether the patient has a good or poor prognosis.

11. (New) The method according to claim 10, wherein the biological sample taken from the patient is a tissue sample.

12. (New) The method according to claim 10, wherein the biological material extracted during step a) comprises nucleic acids.

13. (New) The method according to claim 12, wherein at least one specific reagent of step b) comprises at least one hybridization probe.

14. (New) The method according to claim 13, wherein at least one hybridization probe is immobilized on a support.

15. (New) The method according to claim 14, wherein the support is a biochip.

16. (Withdrawn-New) The method according to claim 10, wherein, during step b), the biological material is brought into contact with reagents specific for a combination of

target genes comprising the nucleic acid sequences set forth in SEQ ID NOs:1 to 37, respectively.

17. (Withdrawn-New) The method according to claim 10, wherein, during step b), the biological material is brought into contact with reagents specific for a combination of target genes comprising the nucleic acid sequences set forth in SEQ ID NOs:1–3, 7–10, 14, 16, 20–22, 25, 27, 29, 31, 34, 36, and 37, respectively.